Omnipod
Tubeless, wearable, waterproof insulin delivery system for diabetes management
Device · EmbeddedCompany source
Company profile
About Insulet
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company founded in 2000 that transforms the lives of people with diabetes through its revolutionary Omnipod insulin delivery system. Born from a father's determination to free his son from the burden of multiple daily insulin injections, Insulet has grown into a global leader in diabetes management technology. The company's flagship product line features tubeless, wearable, waterproof Pod-based insulin management systems that provide continuous insulin delivery without the constraints of traditional tubed pumps. Headquartered in Acton, Massachusetts, with manufacturing facilities and offices around the world, Insulet serves over 600,000 customers across 25 countries in North America, Europe, the Middle East, and Asia Pacific. The company's Omnipod 5 Automated Insulin Delivery System represents a breakthrough in diabetes care as the first truly wearable, automated insulin delivery system controlled by a smartphone. With $2.7 billion in 2025 revenue and recognition as the #1 U.S. requested and prescribed automated insulin delivery (AID) system, Insulet continues to advance its mission of creating a world where diabetes demands less every day, everywhere. The company maintains a strong commitment to quality, safety, and sustainability while continuously innovating to improve outcomes for the diabetes community.
Company description Insulet official website
Primary marketChronic Disease Management & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Insulet?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Insulin-dependent Diabetes
- Type 1 Diabetes
Who it serves
- Caregivers
- Consumers
- People with diabetes
Deployment & integration
Embedded deployment with recorded integration context.
Geographic context
MarketsAsia Pacific · Canada · Europe · Middle East · United States
Company sourceOfficial website
Company milestones
Platform expansion
Omnipod 5 Automated Insulin Delivery System launched as first truly wearable, automated insulin delivery system controlled by phone. Achieved #1 position for U.S. requested and prescribed AID system. Expanded to 25 countries globally.
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Omnipod 5 Automated Insulin Delivery System
#1 U.S. requested and prescribed AID system with smartphone control
Device · EmbeddedCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12-Month Extension of a Randomized Controlled Trial.Endocrinology, diabetes & metabolism · Sep 1, 2026
Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost-Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden.Diabetes, obesity & metabolism · Aug 17, 2026
Simplifying meal bolusing with Omnipod 5: real-world outcomes to support simplified user-initiated insulin dosing strategies in managing type 1 or type 2 diabetes.Diabetes research and clinical practice · Jul 17, 2026
Diabetes-related acute care utilization following initiation of automated insulin delivery (AID): A comparison of a disposable tubeless AID system and durable tubed systems.Journal of managed care & specialty pharmacy · Jul 9, 2026
Settings Associated with Optimal Glycemic Outcomes with the Omnipod® 5 Automated Insulin Delivery System: Evidence from Real-World Users with Type 1 Diabetes.Diabetes technology & therapeutics · Jun 24, 2026
Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System.Diabetes technology & therapeutics · May 1, 2026
Clinical validation
Clinical-trial records
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 DiabetesNCT07521475 · Sponsor · RECRUITING
Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)NCT07317102 · Sponsor · RECRUITING
French Prospective Multicentric Study in Real WorldNCT07039942 · Sponsor · ACTIVE NOT RECRUITING
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 SystemNCT07579702 · Sponsor · RECRUITING
Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1DNCT07593625 · Sponsor · RECRUITING
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 DiabetesNCT06144554 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
#1 U.S. requested and prescribed AID system
Omnipod 5 product specific as of 2025
600,000+ global customers
As of 2025
$2.7B revenue
2025 annual revenue
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Insulet
Recent articles published on Insulet's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Chronic Disease Management & Digital Therapeutics
Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.